China plans to launch some 40 Beidou navigation satellites by 2020 to support its global navigation and positioning network, which will provide global coverage with positioning accuracy of less than 10 metres and timing accuracy of 20 nanoseconds. Major navigation systems, such as the US-based GPS and Russia's GLONASS, use about 24 satellites, but Beidou, with 35 satellites, will be more accurate after it achieves global coverage. (China to launch about 40 Beidou satellites by 2020, by the Times of India)
With more and more satellites launched, the independent research and development positioning system, Beidou Navigation System has shown a promising application prospect, which may play an important role in areas like national security, maritime transport and scientific research in China .
Many industry experts believe that a new era of Chinese innovation in bio-pharma may be soon upon us. The excitement of pharmaceutical executives and investors at the recent BioCentury China healthcare conference was palpable, fueled by a flurry of new measures announced by the China Food and Drug Administration (CFDA), following guidance by the State Council. (This is What Industry Experts Told us About Pharma Innovation in China, by McKinsey)
CFDA have taken a series of measures to promote bio-medical as a strategic industry. Changes at the top of the CFDA, real efforts to clear the backlog of new drug applications, the continuous wave of returning talent, and improving funding conditions are indicators that China is well on its way to becoming a biopharma innovation powerhouse.